Clinical trial
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate…
NCT00003517 · Burzynski Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00003517 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention and 4 more |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: